{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:39:10Z","timestamp":1786981150966,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10593-0","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:38:05Z","timestamp":1767922685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The DIGIT-HF trial and the Mihai Gheorghiade legacy: time to reconsider cardiac glycosides as effective therapy in HFrEF"],"prefix":"10.1007","volume":"31","author":[{"given":"Oliviana","family":"Geavlete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Skowronski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Alexy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Monzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"5 Suppl A","key":"10593_CR1","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/S0735-1097(85)80457-5","volume":"5","author":"DM Krikler","year":"1985","unstructured":"Krikler DM (1985) The foxglove, the old woman from Shropshire and William Withering. J Am Coll Cardiol 5(5 Suppl A):3A-9A","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10593_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jacc.2014.01.051","volume":"63","author":"AP Ambrosy","year":"2014","unstructured":"Ambrosy AP, Butler J, Ahmed A, Vaduganathan M, van Veldhuisen DJ, Colucci WS et al (2014) The use of Digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol 63(18):1823\u20131832","journal-title":"J Am Coll Cardiol"},{"issue":"28","key":"10593_CR3","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/eurheartj\/ehv143","volume":"36","author":"M Vamos","year":"2015","unstructured":"Vamos M, Erath JW, Hohnloser SH (2015) Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36(28):1831\u20131838","journal-title":"Eur Heart J"},{"issue":"1","key":"10593_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26\u201335","journal-title":"Eur Heart J"},{"issue":"11","key":"10593_CR5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2014) Angiotensin-neprilysin Inhibition versus Enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"18","key":"10593_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273(18):1450\u20136","journal-title":"JAMA"},{"issue":"8","key":"10593_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ejhf.2952","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Girerd N, Duarte K, Ferreira JP, McMurray JJV, van Veldhuisen DJ et al (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial. Eur J Heart Fail 25(8):1444\u20139","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10593_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"Suppl C","key":"10593_CR9","doi-asserted-by":"publisher","first-page":"C309","DOI":"10.1093\/eurheartjsupp\/suad055","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Ferrari I, Cicogna F, Tota C, Cice G, Girerd N et al (2023) Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. Eur Heart J Suppl 25(Suppl C):C309\u2013C15","journal-title":"Eur Heart J Suppl"},{"issue":"10254","key":"10593_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819\u201329","journal-title":"Lancet"},{"issue":"18","key":"10593_CR11","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"1","key":"10593_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al (2022) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 24(1):4\u2013131","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10593_CR13","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1002\/ehf2.14076","volume":"9","author":"GMC Rosano","year":"2022","unstructured":"Rosano GMC, Seferovic P, Savarese G, Spoletini I, Lopatin Y, Gustafsson F et al (2022) Impact analysis of heart failure across European countries: an ESC-HFA position paper. ESC Heart Fail 9(5):2767\u201378","journal-title":"ESC Heart Fail"},{"key":"10593_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415471","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek U, Grosshennig A, Schwab J, Berliner D, Rieth A, Maier LS et al (2025) Digitoxin in patients with heart failure and reduced ejection fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2415471","journal-title":"N Engl J Med"},{"issue":"8","key":"10593_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/ehjcvp\/pvab079","volume":"8","author":"CJ Kapelios","year":"2022","unstructured":"Kapelios CJ, Lund LH, Benson L, Dahlstrom U, Rosano GMC, Hauptman PJ et al (2022) Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish heart failure registry. Eur Heart J Cardiovasc Pharmacother 8(8):756\u2013767","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10593_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cardfail.2004.07.002","volume":"11","author":"M Domanski","year":"2005","unstructured":"Domanski M, Fleg J, Bristow M, Knox S (2005) The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail 11(2):83\u201386","journal-title":"J Card Fail"},{"issue":"5","key":"10593_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1751-7133.2010.00161.x","volume":"16","author":"J Butler","year":"2010","unstructured":"Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN (2010) Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail 16(5):191\u20135","journal-title":"Congest Heart Fail"},{"issue":"4","key":"10593_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-N","volume":"22","author":"BF Uretsky","year":"1993","unstructured":"Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK (1993) Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 22(4):955\u201362","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10593_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199307013290101","volume":"329","author":"M Packer","year":"1993","unstructured":"Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ et al (1993) Withdrawal of Digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study. N Engl J Med 329(1):1\u20137","journal-title":"N Engl J Med"},{"issue":"8","key":"10593_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"Group DI","year":"1997","unstructured":"Digitalis Investigation Group(1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525\u201333","journal-title":"N Engl J Med"},{"issue":"5","key":"10593_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/eurjhf\/hft010","volume":"15","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG et al (2013) Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 15(5):551\u20139","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10593_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27(2):178\u201386","journal-title":"Eur Heart J"},{"issue":"2","key":"10593_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cardfail.2003.12.005","volume":"10","author":"WB Hood Jr.","year":"2004","unstructured":"Hood WB Jr., Dans AL, Guyatt GH, Jaeschke R, McMurray JJ (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 10(2):155\u201364","journal-title":"J Card Fail"},{"issue":"4","key":"10593_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00228-023-03470-y","volume":"79","author":"G Gazzaniga","year":"2023","unstructured":"Gazzaniga G, Menichelli D, Scaglione F, Farcomeni A, Pani A, Pastori D (2023) Effect of Digoxin on all-cause and cardiovascular mortality in patients with atrial fibrillation with and without heart failure: an umbrella review of systematic reviews and 12 meta-analyses. Eur J Clin Pharmacol 79(4):473\u2013483","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10593_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2018.09.036","volume":"123","author":"M Vamos","year":"2019","unstructured":"Vamos M, Erath JW, Benz AP, Lopes RD, Hohnloser SH (2019) Meta-analysis of effects of Digoxin on survival in patients with atrial fibrillation or heart failure: an update. Am J Cardiol 123(1):69\u201374","journal-title":"Am J Cardiol"},{"issue":"11","key":"10593_CR26","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.jacc.2003.07.020","volume":"42","author":"AU Khand","year":"2003","unstructured":"Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG (2003) Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42(11):1944\u20131951","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10593_CR27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1536\/ihj.20.623","volume":"20","author":"M Takahashi","year":"1979","unstructured":"Takahashi M, Sada T, Taneichi Y, Okabe F, Ito Y, Morishima A (1979) Some observations on serum concentrations of digitoxin and digoxin. Jpn Heart J 20(5):623\u2013629","journal-title":"Jpn Heart J"},{"issue":"5","key":"10593_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/0033-0620(84)90012-4","volume":"26","author":"TW Smith","year":"1984","unstructured":"Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD (1984) Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 26(5):413\u2013458","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"10593_CR29","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/01.CIR.84.5.2181","volume":"84","author":"M Gheorghiade","year":"1991","unstructured":"Gheorghiade M, Ferguson D (1991) Digoxin. A neurohormonal modulator in heart failure? Circulation 84(5):2181\u20136","journal-title":"Circulation"},{"key":"10593_CR30","doi-asserted-by":"crossref","unstructured":"Gheorghiade M, Adams KF Jr., Colucci WS (2004) Digoxin in the management of cardiovascular disorders. Circulation 109(24):2959\u201364","DOI":"10.1161\/01.CIR.0000132482.95686.87"},{"issue":"1","key":"10593_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0735-1097(89)90561-5","volume":"13","author":"M Gheorghiade","year":"1989","unstructured":"Gheorghiade M, Hall V, Lakier JB, Goldstein S (1989) Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 13(1):134\u2013142","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10593_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ejhf.1452","volume":"21","author":"U Bavendiek","year":"2019","unstructured":"Bavendiek U, Berliner D, Davila LA, Schwab J, Maier L, Philipp SA et al (2019) Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur J Heart Fail 21(5):676\u201384","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10593_CR33","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"15","key":"10593_CR34","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"key":"10593_CR35","unstructured":"Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M et al (2025) Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet"},{"issue":"7","key":"10593_CR36","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/ejhf.3679","volume":"27","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek U, Thomas NH, Berliner D, Liu X, Schwab J, Rieth A et al (2025) DIGitoxin to improve outcomes in patients with advanced chronic heart failure (DIGIT-HF): baseline characteristics compared to recent randomized controlled heart failure trials. Eur J Heart Fail 27(7):1224\u201333","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10593_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ejhf.3575","volume":"27","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek U, Berliner D, Thomas NH, Liu X, Schwab J, Rieth A et al (2025) The DIGIT-HF trial: key amendments of study design. Eur J Heart Fail 27(3):606\u20138","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10593_CR38","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382(20):1883\u20131893","journal-title":"N Engl J Med"},{"issue":"4","key":"10593_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/ejhf.3618","volume":"27","author":"H Skouri","year":"2025","unstructured":"Skouri H, Girerd N, Monzo L, Petrie MC, Bohm M, Adamo M et al (2025) Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 27(4):707\u201322","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10593_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021094","volume":"10","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J et al (2021) Blood pressure and safety events with vericiguat in the VICTORIA trial. J Am Heart Assoc 10(22):e021094","journal-title":"J Am Heart Assoc"},{"issue":"9744","key":"10593_CR41","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"M Bohm","year":"2010","unstructured":"Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886\u201394","journal-title":"Lancet"},{"issue":"9","key":"10593_CR42","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/eurheartj\/ehs004","volume":"33","author":"D Castagno","year":"2012","unstructured":"Castagno D, Petrie MC, Claggett B, McMurray J (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33(9):1137\u20131141","journal-title":"Eur Heart J"},{"issue":"8","key":"10593_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.14740\/jocmr4772","volume":"14","author":"A Jabri","year":"2022","unstructured":"Jabri A, Alhuneafat L, Shahrori Z, Hamade H, Nasser F, Rayyan A et al (2022) Impact of Digoxin use on Guideline-Directed medical therapy in patients with heart failure with reduced ejection fraction. J Clin Med Res 14(8):315\u2013320","journal-title":"J Clin Med Res"},{"issue":"10","key":"10593_CR44","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ejhf.3428","volume":"26","author":"DJ van Veldhuisen","year":"2024","unstructured":"van Veldhuisen DJ, Rienstra M, Mosterd A, Alings AM, van Asselt ADJ, Bouvy ML et al (2024) Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial. Eur J Heart Fail 26(10):2223\u201330","journal-title":"Eur J Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10593-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10593-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10593-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:03:03Z","timestamp":1767927783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10593-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10593"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10593-0","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"A.P.A. has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute (K23HL150159 and R01AG091005), the American Heart Association, The Permanente Medical Group, Kaiser Permanente Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Amarin Pharma, Inc., Bayer Pharma AG, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis and has been a consultant to Bayer Pharma AG, Corstasis, Merck, Novo Nordisk, Pharmacosmos A\/S, scPharma, Reprieve Cardiovascular, and VisCardia. T.A. serves as consultant and is on the speaker\u2019s bureau for Abbott, Edwards Life Sciences, scPharmaceuticals and CVRx. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens. O.C. has received grants from Servier. L.M. has received a travel grant from Boehringer Ingelheim. All conflicts of interest have been declared outside the present work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"18"}}